You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Small Molecule Inhibitor of Rheumatoid Arthritis

    SBC: A&G PHARMACEUTICAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Lck is a Src family non-receptor tyrosine kinase expressed by T lineage lymphocytes. In T cells, Lck plays an essential role in the generation of antigen-mediated activation signals. Since T cell activation is central to mounting immune response, inhibition of Lck blocks T cell activation and suppresses the immune response. Accordingly, Lck serves as an ideal ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Autoantibody Profiling for Serological Detection of Head and Neck Cancer

    SBC: 20 20 Genesystems Inc            Topic: N/A

    DESCRIPTION (provided by applicant): SBIR grant support is being sought by 20/20 GeneSystems, Inc. (20/20), a small biotech company, to help us advance what we believe will become the first blood test to be routinely employed to aid in the early detection of head and neck cancer. Despite recent advances in both diagnostic and therapeutic modalities, long-term prognosis for patients affected by adv ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Profiling Autoantibodies in Non-small Cell Lung Cancer with Fusion Protein-Peptid

    SBC: 20 20 Genesystems Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 135,000 new cases of non-small cell lung cancer (NSCLC) are diagnosed each year in the USA, yet only 20%-25% of those patients will be diagnosed at a sufficiently early stage to be cured by surgical or other procedures. When used in concert with radiographic imaging, a sensitive and specific blood test for NSCLC could be a clinically valuable and ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Diagnostic Influenza RT-PCR Array

    SBC: AKONNI BIOSYSTEMS INC            Topic: N/A

    DESCRIPTION (provided by applicant): Influenza viruses are highly contagious negative-sense RNA viruses cause approximately 114,000 hospitalizations and 20,000 deaths annually. Several drugs are approved by the US Food and Drug Administration (FDA) for treating influenza infections, but successful treatment depends on knowing the specific antigenic subtype and administering these drugs within the ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a humanized anti-CD47 antibody for treatment of tissue ischemia.

    SBC: VASCULOX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Nitric oxide (NO) is a critical regulator of cardiovascular physiology, coordinating the activities of the endothelium, the vessel wall and circulating cells to optimize the flow of blood and oxygen to tissues. Increasing the bioavailability of NO should provide therapeutic benefit in the treatment of many diseases ascribed to insufficient NO bioavailability. A ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Treatment of Transplant Reperfusion with an Anti-CD47 Antibody

    SBC: VASCULOX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs. Current practice involves donor preconditioning to stabilize organs and tissues for transplant in attempts to increase the supply of donor organs acceptable for transpl ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Dual Antigen Nanoparticle Vaccine System For Bacillus Infectious Disease

    SBC: APARNA BIOSCIENCES CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Development of rationally designed vaccines is an important need that nanotechnology has tremendous potential to transform. Already nanoparticle developments are incorporated into approved small molecule therapeutics. Advances are making rapid progress toward ligand targeted nanoparticles exhibiting tissue selective delivery, which is precisely one of the key r ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Novel Bioprocess Platform for Rapid, Economical Production of Pept

    SBC: APC BIOTECHNOLOGY SERVICES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A novel bioprocess platform, involving synthesis of peptide and protein biopharmaceutical products as fusions with a synthetic anchor protein in bacteria, and subsequent proteolytic cleavage, has been developed. The unique features of the system allow for the economical production of large quantities of simple linear peptides, as well as complex, multi-compon ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Adjunctive Use of Apyrase to Fibrinolytic Therapy

    SBC: APT THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered human apyrases which exhibit both antiplatelet and anti-inflammatory activities. With the Phase I gran ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Apyrase to treat ischemia/reperfusion injury during lung transplantation

    SBC: APT THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy to prevent or reduce ischemia-reperfusion injury during lung transplantation. The enzyme strongly preserves vascular integrity and inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics approach, we have successfully engineered an optimized human apyrase, APT ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government